… of SARS-CoV-2–infected individuals was conducted to assess whether subcutaneous casirivimab
and imdevimab… In Part A of the trial, casirivimab and imdevimab significantly prevented …

… We evaluated the effect of casirivimab/imdevimab treatment … swabs for the detection of
SARS-CoV-2 and Next-Generation … A cocktail of casirivimab/imdevimab was administrated, and …

… predominant variant and positivity of SARS-CoV-2 polymerase chain reaction … SARS-CoV-2
in a cohort of healthcare workers. Patients were given 2 doses of casirivimab and imdevimab …

… were SARS-CoV-2 RT-qPCR positive, casirivimab and imdevimab … SARS-CoV-2 seronegative
at baseline. Viral load showed similar reductions across all casirivimab and imdevimab …

… Meaning Findings of this study suggest that casirivimab-imdevimab and sotrovimab were
both associated with reduced risk of hospitalization or death and had similar effectiveness, …

… antibodies (casirivimab and imdevimab) against the spike protein of the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease …

… -SARS-CoV-2 mAbs, casirivimab and imdevimab, which bind specifically to the receptor
binding domain of the spike glycoprotein of SARS-CoV-2… -hospitalised adults with SARS-COV-2 …

… Monoclonal antibody therapies that block the virus that causes COVID-19 (SARS-CoV-2) …
combination of casirivimab and imdevimab (CAS + IMD) can decrease the amount of virus in …

… antibody combination casirivimab and imdevimab (CAS + IMD) prevented symptomatic
SARS-CoV-2 infections by 81·4% in generally healthy household contacts of SARS-CoV-2-…

… and imdevimab), has been shown to reduce … 5, 6 Casirivimab and imdevimab are 2 IgG1
antibodies that are noncompeting, and they target the receptorbinding domain of the SARS-CoV…